1-5 of 5
Chhaya Sankhalpara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Free
Daniel Wiseman, Jak Laight, Rebecca Boucher, Chhaya Sankhalpara, Rebecca Record, Jennifer Byrne, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Srinivasan Narayanan, Rob Sellar, Kiran Batta, Manoj Raghavan, Dr. Emma Searle, Catherine Cargo, Steve Knapper, Austin Kulasekararaj
Journal: Blood
Blood (2025) 146 (Supplement 1): 488.
https://doi.org/10.1182/blood-2025-488
Published: 2025
Journal Articles

Fedora preliminary analysis of a Phase II study evaluating the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis.

Free
Mary Frances McMullin, Fitsum Ghebretinsea, Rebecca Boucher, Sebastian Francis, Gillian Horne, Hayder Hussein, Steve Knapper, Donal McLornan, Srinivasan Narayanan, Jennifer O Sullivan, Tim Somervaille, Chun Teh, Frances Wadelin, Chhaya Sankhalpara, Emily Yafai, Catherine Thomas, Rupen Hargreaves, Nawshad Hayder, Graham Mcllroy, Claire Harrison, Adam Mead
Journal: Blood
Blood (2025) 146 (Supplement 1): 486.
https://doi.org/10.1182/blood-2025-486
Published: 2025
Journal Articles

Patient experience sub-study of a randomised UK multicentre Phase 2 trial of ASTX727 versus hydroxycarbamide/best supportive care in myelodysplastic (MDS)/myeloproliferative (MPN) overlap syndromes (AMMO)

Free
Ashleigh Ward, Sally Taylor, Grant Punnett, Ramsay Devaraj, Chhaya Sankhalpara, Rebecca Record, Kiran Batta, Jennifer Byrne, Catherine Cargo, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Steve Knapper, Austin Kulasekararaj, Srinivasan Narayanan, Manoj Raghavan, Rob Sellar, Daniel Wiseman, Janelle Yorke
Journal: Blood
Blood (2025) 146 (Supplement 1): 8164.
https://doi.org/10.1182/blood-2025-8164
Published: 2025
Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Free
Talha Munir, Louise-Rae Cherrill, Nichola Webster, Surita Dalal, Rebecca H. Boucher, Chhaya Sankhalpara, Francesca Yates, Sonia Fox, Donald Macdonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P Fox, Francesco Forconi, Andy C. Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 222–223.
https://doi.org/10.1182/blood-2022-166700
Published: 2022
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Free
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020